Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Founder Securities initiates coverage on Sino Biopharmaceuticals (01177) with a strongly recommended rating, bullish on its innovative empowerment and international expansion trend.
Founder Securities' research report stated that Sino Biopharm is entering a period of comprehensive transformation and innovation with four main focuses of self-research and development + BD layout. The company is actively exploring four key innovative areas in oncology, liver disease, respiratory, and surgery/pain, with rich technology layout and accelerated clinical speed, achieving rapid growth in revenue from innovative products. The bank expects the company's revenue to be RMB 29.727 billion, RMB 33.577 billion, and RMB 38.427 billion from 2024 to 2026, with year-on-year growth rates of 12.7%, 12.95%, and 14.44%, and net income of RMB 39.11.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
HKEX movements: Zhongsheng Pharmaceutical (01177) up more than 4%, implementing its first share incentive plan since going public; management remains optimistic about double-digit growth for the year.
China Biopharma (01177) is now up more than 4%. As of press time, it has increased by 4.03%, to 2.84 Hong Kong dollars, with a turnover of 0.123 billion Hong Kong dollars.
Daiwa: Upgraded Sino Biopharm's rating to "buy", target price raised to HKD 3.2.
Daiwa released a research report stating that due to the increase in sales of innovative products under Sino Biopharmacy (01177) and higher business growth prospects from 2024 to 2025. Daiwa has raised the target price of Sino Biopharmacy from HKD 3.1 to HKD 3.2 and upgraded its rating from "outperform market" to "buy". The report quoted management as stating that the company remains optimistic about achieving double-digit year-on-year growth in revenue and net income in the 2024 fiscal year, driven by innovative products. Management also believes that the macroeconomic environment in the second half of this year will provide a more investment-friendly environment for the pharmaceutical industry. Daiwa expects...
Sino Biopharm (01177) rose over 3% on the Hong Kong Stock Connect and its diabetes drug Baquting was approved for listing in the mainland.
Sino Biopharm (01177) stocks rose in early trading to a high of 2.72 Hong Kong dollars, up 3.03%. As of press time, it was reported at 2.71 Hong Kong dollars, up 2.65%, with a turnover of 44.4028 million Hong Kong dollars. The group's developed "Liraglutide Injection" (commodity name: Belulin) has obtained the listing approval of the China National Medical Products Administration and is used for adults with type 2 diabetes to control blood sugar. Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) analogue, which has 97% homology with natural GLP-1. GLP-1 is an endogenous enteroinsular insulin stimulating hormone.
Sino Biopharmaceutical's "Liraglutide Injection" has been approved for sale and is used to control blood sugar in adult type 2 diabetes patients.
Sino Biopharm (01177.HK) announced on June 25th that the group's developed product 'Liraglutide Injection' (commodity name: Belulin) has been approved for listing in China by the National Medical Products Administration, for controlling blood sugar in adult Type 2 diabetes patients. Liraglutide is a long-acting GLP-1 analogue, with 97% homology to natural GLP-1. GLP-1 is an endogenous intestinal incretin hormone that enhances glucose-dependent insulin secretion in pancreatic β cells. In addition to pancreatic cells, GLP-1 receptors are also widely present in the gastrointestinal tract, lung,
Express News | Sino Biopharmaceutical - Liraglutide Injection Got Approval for Marketing From Nmpa China
Express News | Sino Biopharmaceutical - Approval for Marketing of "Liraglutide Injection"
Sino Biopharmaceutical Completes Issuance of 1.5 Billion Yuan in Panda Bonds
Sino Biopharmaceutical (HKG:1177) completed the issuance of 1.5 billion yuan in Panda bonds, according to a Thursday filing with the Hong Kong Stock Exchange. The bonds have an interest rate of 1.95%
Sino Biopharmaceutical Completes Issuance of 1.5 Billion Panda Bonds
Sino Biopharmaceutical (HKG:1177) said it completed the issuance of 1.5 billion yuan panda bonds, according to a Thursday filing on the Hong Kong bourse. The bonds have a 1.95% coupon rate and mature
Sino Biopharm (01177.HK): Zhongda Tianqing purchases shares according to the stock incentive plan.
On June 20th, Gelunhui reported that Sino Biopharmaceuticals (01177.HK) announced that between June 14th and June 20th, 2024, the trustee further purchased a total of 18.336 million shares of the company's stock on the market in accordance with the terms and conditions of the stock incentive plan, for subsequent share incentives to selected participants.
Sino Biopharm (01177.HK): completes the issuance of the first batch of panda bonds.
Sino Biopharm (01177.HK) announced on June 20 that the company has completed the issuance of the first batch of panda bonds. According to the bookkeeping and subscription results, the total issuance size of the first batch of panda bonds is RMB 1.5 billion, with an issuance interest rate of 1.95% and a term of 180 days. The issuance of the first batch of panda bonds aims to actively explore diversified financing channels and reduce the company's funding costs. The group always maintains a sound financial planning and has strong funding strength. The issuance of panda bonds this time will further optimize the group's financing structure, enhance its financial performance, and also demonstrate the group's strength in financial innovation.
Sino Biopharmaceutical Gets Marketing Go-Ahead for Lung Cancer Drug in China
Sino Biopharmaceutical (HKG:1177) has obtained marketing approval for its Envonalkib tablets from China's National Medical Products Administration, a Wednesday filing by the pharmaceutical company wit
Sino Biopharm (01177.HK): Type 1 innovative drug Envonalkib (TQ-B3139) in citrate form has been approved for listing.
Sino Biopharmaceutical announced on June 19th that the group's independently developed class 1 innovative drug, envonalkib (TQ-B3139) (trade name: Anluoqing), which is a capsule of citrate enfonidacil, has been granted approval for marketing by the China National Medical Products Administration. It is used for the treatment of local advanced or metastatic non-small cell lung cancer (NSCLC) patients who are ALK-positive but have not received an ALK inhibitor. Enfonidacil is a new type of ALK inhibitor independently developed by the group, and this indication is for first-line treatment of ALK-positive NSCLC.
Express News | Sino Biopharmaceutical - Envonalkib (Tq-B3139) Obtained Approval for Marketing From Nmpa of China
First Shanghai maintains a "buy" rating for Sino Biopharm (01177) with a target price of HKD 3.25.
First Shanghai expects that innovative products in 2025 will account for 47% of Sino Biopharm's (01177) revenue.
Sino Biopharm Trustee Purchases 15.8 Million Shares Under Incentive Scheme
The trustee of Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing purchased 15.8 million shares between June 5 and June 13 under a share award scheme, according to a Thursday filing with the Hon
Sino Biopharm (01177.HK): SDIC Tianqing Pharmaceutical Co., Ltd. Incentive Plan Buys Shares
Sino Biopharm (01177.HK) announced that on May 7, 2024, China Biopharmaceuticals Co., Ltd. made an announcement on the implementation of equity incentive plan for its subsidiary, Zhejiang Jingxin Tianqing Pharmaceutical Group Co., Ltd. ("Jingxin Tianqing"). From June 5, 2024 to June 13, 2024, the trustee purchased a total of 15.842 million shares of the company on the market according to the terms and conditions of the share incentive plan, which will be used for subsequent implementation of share incentives for selected participants.
No Data